Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631299 | 0.83 | TDP1 (0.48) | SIGMAR1L3MBTL1TDP1CES1NAAA | |
| SCHEMBL626848 | 0.80 | TDP1 (0.61) | SIGMAR1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL7448881 | 0.80 | TDP1 (0.61) | SIGMAR1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL7449055 | 0.80 | TDP1 (0.61) | SIGMAR1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL8048487 | 0.80 | TDP1 (0.61) | SIGMAR1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL7449325 | 0.80 | TDP1 (0.61) | SIGMAR1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL198056 | 0.78 | IDO1 (0.58) | SIGMAR1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL23014825 | 0.77 | L3MBTL1 (0.58) | SIGMAR1L3MBTL1TDP1 | |
| SCHEMBL22281733 | 0.77 | L3MBTL1 (0.58) | SIGMAR1L3MBTL1TDP1 | |
| SCHEMBL12040626 | 0.77 | L3MBTL1 (0.58) | SIGMAR1L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0947513-B1 | TRICYCLIC AMINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6586604-B2 | Antimicrobial activity versus gram negative and gram positive bacteria | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6384050-B1 | GASTROINTESTINAL DISORDERS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-20010037030-A1 | Tricyclic amine derivatives | TAKEMURA MAKOTO (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-0947513-A1 | TRICYCLIC AMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037030-A1 | Tricyclic amine derivatives | Q6ZSR9, TOP2A, TOP1 | SIGMAR1 387/4885L3MBTL1 2263/4885TDP1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.